Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
April 20, 2023 07:30 ET | Sensei Biotherapeutics
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
April 18, 2023 16:05 ET | Sensei Biotherapeutics
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
April 13, 2023 07:30 ET | Sensei Biotherapeutics
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
March 30, 2023 07:30 ET | Sensei Biotherapeutics
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
March 28, 2023 07:30 ET | Sensei Biotherapeutics
- Investigational New Drug (IND) application submitted for lead candidate SNS-101, a conditionally active VISTA-blocking antibody -- New collaborations with Regeneron, the National Cancer Institute...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
March 21, 2023 07:30 ET | Sensei Biotherapeutics
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023 16:35 ET | Sensei Biotherapeutics
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
March 07, 2023 17:15 ET | Sensei Biotherapeutics
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
March 06, 2023 07:30 ET | Sensei Biotherapeutics
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer...
Sensei_Logo_RGB_Logo_Full-Color.png
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
February 21, 2023 07:30 ET | Sensei Biotherapeutics
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...